anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The current incidence of chronic kidney disease-associated pruritus (CKD-aP) in patients with end-stage renal disease (ESRD) is approximately 70%, especially in those receiving dialysis, which negatively affects their work and private lives. The CKD-aP pathogenesis remains unclear, but uremic toxin accumulation, histamine release, and opioid imbalance have been suggested to lead to CKD-aP. Current therapeutic approaches, such as opioid receptor modulators, antihistamines, and ultraviolet B irradiation, are associated with some limitations and adverse effects. The skin barrier is the first defense in preventing external injury to the body. Patients with chronic kidney disease often experience itch due to the damaged skin barrier and reduced secretion of sweat and secretion from sebaceous glands. Surprisingly, skin barrier-repairing agents repair the skin barrier and inhibit the release of inflammatory cytokines, maintain skin immunity, and ameliorate the micro-inflammatory status of afferent nerve fibers. Here, we summarize the epidemiology, pathogenesis, and treatment status of CKD-aP and explore the possibility of skin barrier repair in CKD-aP treatment.
The effects of diltiazem hydrochloride extended-release tablets on angina were evaluated in a randomized, double-blind, parallel-group, dose-response trial of 311 patients with chronic stable angina. Evening doses of 180, 360, and 420 mg were compared to placebo and to 360 mg administered in the morning. All doses of diltiazem hydrochloride extended-release tablets administered at night increased exercise tolerance when compared with placebo after 21 hours. The mean effect, placebo-subtracted, was 20 to 28 seconds for all three doses, and no dose-response was demonstrated. Diltiazem hydrochloride extended-release tablets, 360 mg, given in the morning, also improved exercise tolerance when measured 25 hours later. As expected, the effect was smaller than the effects measured only 21 hours following nighttime administration. Diltiazem hydrochloride extended-release tablets had a larger effect to increase exercise tolerance at peak serum concentrations than at trough.
While conventional balance training facilitates balance control and gait functions, the exercises involved in the training are labor-intensive, highly repetitious leading to monotonicity and decreased motivation levels. Therefore, many health care researchers are involved in identifying various methods to reduce the risk of falls addressing the barriers in conventional training methods while having the potential to translate it at home. Pilot studies with dance-based exergaming resulted in improving balance control and cognition post-stroke. Based on this preliminary finding, this current study aimed to identify:

1. The evaluate using the randomized controlled trial the efficacy of dance-based exergaming on physical function compared to conventional standard of care (fall prevention and balance training) among people with chronic stroke This pilot studies used Wii-fit Nintendo/ Microsoft Kinect, an off the shelf, commercially available and a cost-effective device that provides similar benefits of exergaming. Community-dwelling people with chronic stroke involved in the study underwent 6 weeks of exergaming or conventional balance training in a tapering manner in a laboratory setting. Participants were assessed for motor and cognitive performance in the laboratory during volitional and reactive balance control while performing a secondary cognitive task. The performance outcome determined the effect on physical function.
Subjects who have undergone a routine test order of NT-proBNP or BNP for suspected Heart Failure (HF). Waste sample blood will then be tested on the RAMP 200 and the RAMP Reader for comparison.
The main objective is to assess the reduction in genital HIV-1 shedding associated with daily acyclovir for suppression of HSV-2 reactivation.

All patients will be treated with the usual antibiotic treatment for any sexually transmitted infections that are diagnosed during the study. In addition, half will receive acyclovir for 8 weeks , whilst the other half will receive a placebo for 8 weeks. The study medication will reverse in the second 8 weeks of the study. The patients will attend the clinic 3 times per week during the first and the last 8 weeks of the study and once every week during the washout period in the middle of the study - for a total of 18 weeks per participant. At each visit genital and oral samples will be collected. A blood sample will also be collected. For women participants, pregnancy test will be performed. The clinic will provide both pre- and post-HIV test counseling.
Novel 5-(subst. phenyl)-oxazolidinones and their sulphur analogs of the general formula I <IMAGE> in which the substituents are defined in Claim 1, are obtained by reacting 2-amino-1(3,4-disubst. phenyl)-ethanols with a carbonic acid derivative or a thiocarbonic acid derivative in an inert solvent while heating in the presence of a basic catalyst. The novel compounds of the general formula I possess valuable pharmacological properties. They exhibit antidopaminergic, antinociceptive and anticonvulsive effects and have a depressant action on the central nervous system and thus have a certain similarity to neuroleptic agents such as chlorpromazine or haloperidol. In addition, the novel compounds possess strong phosphodiesterase-inhibiting properties and thus affect the metabolism of cyclic nucleotides. The compounds are also suitable for treating hyperproliferative diseases and diseases associated with uncontrolled cell growth.
Patients will receive twice weekly blue light treatment with the Multiclear device. The first treatment dose will be 75mJ/cm2 ( Minimum Effective Dose;MED) for all patients. If no erythema develops, the subsequent treatment dose can be increased by 0.5 MED. If mild to moderate erythema develops, the same dose (i.e. 1 MED) will be used.If severe erythema/ blisters develop, treatment will be stopped and the patient wil be invited one week later and treatment will be offered at 50% of the last dose.

During the first consultation, patients will be assessed for the presence of striae distensae (SD). Duration and previous treatments of SD will be recorded. The width of the widest striae and the length of the longest straie will be measured at baseline and after 2 months of treatment. Photographs will be taken at baseline and post treatment. These will be evaluated by dermatologists who will be blinded (i.e. details of which photographs are pre or post treatment will not be given). Subjective scores will be used (Very good to excellent; \>75%, Good; 51-75%, Moderate; 26-50%, Minimal to no improvement; \<25%) Participants will also be given a feedback form to rate any improvements noted and any side effects experienced.
To gather preliminary research about the feasibility of an EMI sexual assault intervention prior to an experimental condition. A small group of freshman women (N=20) will participate in an EMI protocol for six weeks, followed by providing feedback about their experience, including issues with phrasing, technical issues, and convenience.
Panretinal photocoagulation thermally ablates the retina to effect the regression of the neovascular process seen with diabetic retinopathy.2-6 Photocoagulative damage also damages the nerve fiber layer in the process. Since this should theoretically be associated with loss of nerve fibers it is expected to manifest as changes in optic nerve head cupping. There is no available literature to support this hypothesis. In fact the only available study done of the subject refuted the hypothesis.7 The study had a retrospective design and was done before any of the current technology to evaluate optic nerve head morphology was available.

Patients with concurrent glaucoma and diabetes often undergo panretinal photocoagulation as a part of their diabetes treatment. Optic disc cupping is a standard outcome measure for glaucoma diagnosis and progression. If PRP were to cause increased cupping, this can be a significant confounder in determining glaucoma progression based on optic nerve cupping. The findings of the study will help us determine as to how much cupping can be attributed to the PRP, if any at all.
To provide a device for injecting a medicament.SOLUTION: A device includes a housing with a container in which a medicament can be held. At its proximal end, the container has a needle and a stopper. The device includes a plunger which at one end, can engage the stopper. At an opposite end, the plunger can engage a first resilient member to move the stopper within the container to inject the medicament from the container. The device includes a collar with distal and proximal ends, the distal end engaging with a carriage and causing its rotation and the proximal end engaging with a second resilient member. The second resilient member can engage with a skin sensor which has distal and proximal ends. At the proximal end, the skin sensor can include an injection site. The housing has a cap which can reduce or prevent a movement of the skin sensor.SELECTED DRAWING: Figure 2
To prevent unpleasant symptoms in medical students during systematic anatomy practice, we aimed to develop and validate a model that predicts the likelihood of these symptoms occurring during practice based on risk factors prior to the start of practice. A total of 452 medical students enrolled from 2014 to 2018 were surveyed before and during practice, with questions regarding their sex, psychological status, subjective symptoms, and allergies. The sum of the scores concerning three subjective symptoms related to the eyes and three subjective symptoms related to the nose and fatigue were defined as the "eye-score" and "mask-score," respectively, and a total score of 7 or more was considered symptomatic. A prediction model was developed based on a generalized linear mixed model; the outcome variable in the model was symptoms during practice, and the explanatory variables were indoor formaldehyde concentration during practice, sex, and pre-practice status, such as the students' psychological state, eye-score, mask-score, and the presence of allergies. Five-fold cross-validation was used to assess internal validity and the prediction model was applied to 110 medical students enrolled in 2021 to assess external validity. The sensitivity and specificity by five-fold cross-validation were 0.843 and 0.314 for eye symptoms and 0.847 and 0.432 for mask symptoms. In the external validity assessment, the sensitivity and specificity were 0.889 and 0.207 for eye symptoms and 0.879 and 0.532 for mask symptoms. The prediction model developed in this study can be used in future measures aimed at preventing symptoms in students.
BACKGROUND: Routine sentinel lymphadenectomy (SLNB) for early-stage HR+/HER2- breast cancer in women ≥70 is discouraged by Choosing Wisely, but whether SLNB can be routinely omitted in women ≥70 with DCIS undergoing mastectomy is unclear. This study aims to evaluate rates of axillary surgery and nodal positivity (pN+) in this population to determine the impact of axillary surgery on treatment decisions.
METHODS: Females ≥70 with DCIS undergoing mastectomy were identified from the National Cancer Database (2012-2020). The rate of upstaging to invasive cancer (≥pT1) or pN+ was assessed. Subset analyses were conducted for ER+ patients. Adjuvant therapies were evaluated among ≥pT1 patients after stratifying by nodal status.
RESULTS: Of 9,030 patients, 1,896 (21%) upstaged to ≥pT1. Axillary surgery was performed in 86% of patients, predominantly sentinel lymphadenectomy (SLNB, 65%). Post hoc application of Choosing Wisely criteria demonstrated that 93% of the entire cohort and 97% of ER+ DCIS patients could have avoided axillary surgery. Nodal positivity was 0.3% among those who didn't upstage, and 12% among those upstaging to ≥pT1, with <2% having pN2-3 disease, irrespective of receptor subtype. Node-positive patients had higher adjuvant therapy usage, but there was no recommendation for adjuvant chemotherapy or radiation for 71% and 66% of pN+ patients, respectively.
CONCLUSIONS: Axillary surgery can be omitted for most patients ≥70 undergoing mastectomy for ER+ DCIS, aligning with recommendations for invasive cancer, and omission can be considered in those with ER- disease. Future guidelines incorporating preoperative imaging, as in the SOUND trial, may aid in identifying patients benefiting from axillary surgery.
PROBLEM TO BE SOLVED: To provide a make-up tool for manicure for which a container for a nail polish removing liq. is unnecessary and which is portable and in which a manucure liq. is successively fed to make coating operation simple and which is pref. for health of the nails. SOLUTION: A manicure liq. L the film of which formed on the nail surface can be washed off with water is filled in a container 1 for a coating liq. and a chip 3 freely rotatably held under a condition where a part of a spherical coating body 4 is faced out from the apex is fixed on the aperture of the apex of the container 1 of the coating liq. and the spherical coating body is energized by means of a spring and when it is not used, it is brought into contact with the edge of the inward apex.
A process and a signal processing unit determine a pneumatic parameter (Pmus) for the spontaneous breathing of a patient. The patient is ventilated mechanically by a ventilator. A lung-mechanical model (20) and a gradient model (22) are preset. The lung-mechanical model (20) describes a relationship between the pneumatic parameter (Pmus) as well as a volume flow signal (Vol′), a volume signal (Vol) and/or a respiratory signal (Sig), which can be measured. The gradient model (22) describes a value for the pneumatic parameter (Pmus) as a function of N chronologically earlier values of the pneumatic parameter (Pmus) or of a variable correlating with the pneumatic parameter (Pmus). N values for the correlating variable are determined at first. At least one additional value is subsequently determined for the pneumatic parameter (Pmus). N chronologically earlier values of the correlating variable, current signal values, the lung-mechanical model (20) and the gradient model (22) are used for this purpose.
The present invention relates to a traditional Chinese medicine liniment for treating white hair and belongs to the technical field of external-use product of Chinese medicinal herb. The traditional Chinese medicine liniment is composed of 10% of anoelica sinensis, 18% of Radix Rehmanniae Praeparata, 18% of cacumen biotae, 18% of polygonum multiflorum thunb (prepared), 18% of black sesame seed and 18% of mulberry. The traditional Chinese medicine liniment of the invention is prepared through the steps of adding 5-10 times of total amount of water, soaking for 1 hour and decocting the water for obtaining solution, and bottling the solution after the solution is cooled. In using, firstly the white hair is pulled out. The preparation of the invention is coated on the hairy root. Then the scalp at the affected part is massaged for 15 minutes for increasing the absorption to the medicine. The traditional medicine liniment of the invention is not added with any antiseptic agent, does not contain any chemical composition harmful to the human body and has low excitation and no anaphylaxis. The white hair of patient can be quickly changed to black. The traditional medicine liniment of the invention settles the problems of great side effect, unremarkable curative effect and long treating time in the prior drug for treating white hair. The traditional medicine liniment of the invention also settles the great hair quality damage and carcinogenic effect caused by long-time using of hair dyes agent for hair dyeing. The traditional medicine liniment of the invention has the advantages of easy using, low production cost and especial suitability for treating the white hair in middle period and early period.
The invention discloses an easy-to-clean volcanic mud mask. The mask is prepared from raw materials in parts by weight as follows: 10-30 parts of volcanic mud, 5-10 parts of seaweed powder, 2-5 parts of lemons, 1-5 parts of loofah, 3-8 parts of cucumbers, 5-10 parts of tomatoes, 8-15 parts of milk, 0.1-0.5 parts of olive oil, 0.3-0.8 parts of honey and 10-45 parts of deionized water. The easy-to-clean volcanic mud mask has a function of deeply cleaning skin, has super moisturizing and moisture retention functions, has a powerful skin repairing function, can whiten, tender and smoothen skin, is free of any additive and cannot cause irritation to skin. Different from paste type volcanic mud masks in the market, the easy-to-clean volcanic mud mask has the advantages of being convenient to use, quick to absorb and easy to clean. The invention further provides a production method of the easy-to-clean volcanic mud mask. The production method is simple to operate, low in cost and worthy popularizing.
The aim of the current study was to assess the associations between genetic risk factors (such as the mutational status of the IGHV gene and polymorphisms of the IL-10 and TNF-α genes) and CLL risk, prognosis, and overall survival. Another goal of this study was to evaluate the multivariate effect of the combination of multiple genetic risk factors (mutational status of the IGHV gene, somatic mutations, DNA CNVs, and cytokine SNPs) on the clinical characteristics and survival of patients. A total of 125 CLL patients and 239 healthy controls were included for comparative SNP analysis. IL-10 (rs1800896 and rs1800872) and TNF-α (rs361525 and rs1800750) SNPs and haplotypes were not associated with CLL risk. The absence of hypermutation in the IGHV gene was shown to be of important prognostic value, being associated with short OS. Further individual risk factors for short OS were an age above 65 years at diagnosis and the presence of somatic mutations and/or CNVs. In our multivariable analysis, the presence of somatic mutations and the IL-10 rs1800872 variant allele, and the association of CNVs with the IL-10 rs1800896 variant allele, were identified as risk factors for short OS. Moreover, the OS in unmutated IGHV patients was additionally affected (decreased) by the presence of CNVs and/or somatic mutations. Similarly, IL-10 rs1800896 modulated the OS in unmutated IGHV patients with CNVs.
Patients who already received the ToggleLoc 2.9 mm soft tissue device in the elbow. No additional surgery will be performed.
The recommended adult dosage for the treatment of mild to moderate active Crohn's disease involving the ileum and/or the ascending colon is 9 mg taken once daily in the morning for up to 8 weeks.

Repeated 8 week courses of ENTOCORT EC can be given for recurring episodes of active disease.

Following an 8 week course(s) of treatment for active disease and once the patient’s symptoms are controlled (CDAI <150), ENTOCORT EC 6 mg is recommended once daily for maintenance of clinical remission up to 3 months. If symptom control is still maintained at 3 months an attempt to taper to complete cessation is recommended. Continued treatment with ENTOCORT EC 6 mg for more than 3 months has not been shown to provide substantial clinical benefit.

Patients with mild to moderate active Crohn’s disease involving the ileum and/or ascending colon have been switched from oral prednisolone to ENTOCORT EC with no reported episodes of adrenal insufficiency. Since prednisolone should not be stopped abruptly, tapering should begin concomitantly with initiating ENTOCORT EC treatment. 

Hepatic Insufficiency: Patients with moderate to severe liver disease should be monitored for increased signs and/or symptoms of hypercorticism. Reducing the dose of ENTOCORT EC capsules should be considered in these patients.

CYP3A4 inhibitors: If concomitant administration with ketoconazole, or any other CYP3A4 inhibitor, is indicated, patients should be closely monitored for increased signs and/or symptoms of hypercorticism. Reduction in the dose of ENTOCORT EC capsules should be considered.

ENTOCORT EC capsules should be swallowed whole and not chewed or broken.
Neutropenia, a common side effect of chemotherapy for ovarian cancer, was observed in a 47-year-old female patient undergoing a six-cycle chemotherapy regimen. She experienced recurrent neutropenia and leukopenia but refused granulocyte colony-stimulating factor (G-CSF) due to severe bone pain and high costs. Moxibustion combined with guasha therapy (MGT) was administered each time neutropenia occurred. The treatment involved guasha therapy on the bladder meridian (BL) and the governor vessel (GV), followed by moxibustion at Zhongwan (CV 12), Guanyuan (CV 4), and Shenzhu (GV 12) points over 2-3 days. This approach led to the recovery of neutrophil and leukocyte counts, enabling the patient to complete six chemotherapy cycles without G-CSF. These findings suggest that MGT may enhance neutrophil and leukocyte counts in patients with chemotherapy-induced myelosuppression, presenting a potential alternative for those intolerant to G-CSF. However, further high-quality research is needed to confirm its efficacy.
55% to 75% of people after stroke have a paretic arm that causes motor impairment. Among novel rehabilitation interventions, MT was found to be beneficial and comparatively low-cost. MT reduced motor impairment possibly in part of recruiting the premotor cortex or balancing the neural activation within the primary motor cortex toward the affected hemisphere. However, the benefits in certain aspects of outcomes are under debate. Another treatment, MG, can be used to normalize muscle tone, suppress muscle spasticity, enhance residual volitional activity of hand and arm, or even increasing walking speed. In addition, providing MG stimulation might result in plastic changes in the primary motor cortex, and induced a long-lasting modulated effect on motor cortical excitability. The possible mechanism of brain plasticity underlying MG is collective with the mechanism behind the MT. Adding MG to MT might augment the cortical reorganization. In sum, combining MT with MG may supplement the disadvantage or uncertain effects of MT and broaden the benefited outcomes.
Radiation with photons normofractionated 54-60 Gy. Not pre-irradiated patients, bening tumors.
Mycioplasma are the smallest and simplest self-replicating prokaryote. The size of mycoplasma genome (700-1500 kb) is one sixth the size of E. coli genome. The extremly low G+C content of mycoplasma DNA further imposes restriction on the amount of genetic information available to mycoplasma cells. The genetic and molecular biology studies of the class just started. Only a few genes were cloned and characterized. Mycoplasma hyopneumoniae is also known as the etiologic agent of mycoplasma pneumoniae of swines, a common disease causes economic loss through slower growth and lower feed efficacy of the swine. The present patent application is based on the 18 kDa protein gene isolated from M. hyopneumoniae genomic library. The 18 kDa protein has been demonstrated to be a membrane surface protein and is part of the 30 kDa protein. The membrane protein has a GTP-binding domain similar to many LepA proteins. The monospecific antibody purified with the protein can inhibit cell growth. Therefore, the recombinant proteins derived from the antigen gene are feasible as potential animal vaccines.